Appropriate analgesia: An evidence-based evaluation of the role of acetaminophen in pain management

American Journal of Therapeutics

Volumn 12, Issue 1, 2005, Pages 43-45

  Whelton, Andrew ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Universal Clinical Research Center Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOOXYGENASE 3; DICLOFENAC; IBUPROFEN; NAPROXEN; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ANALGESIA; DIZZINESS; DRUG MECHANISM; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; HUMAN; PAIN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PRURITUS; RASH; REVIEW; WHEEZING;

EID: 17144381329     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-200501000-00007     Document Type: Review

References (11)

1. Schnitzer TJ. Update of ACR guidelines for osteoarthritis: role of the coxibs. J Pain Symptom Manage. 2002;23:S24-S30.
2. Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62:1145-1155.
3. FitzGerald GA. Coxibs and cardiovascular disease. N Engl J Med. 2004;351:1709-1711.
4. Sinclair HK, Bond CM, Hannaford PC. Long term follow-up studies of users of nonprescription medicines purchased from community pharmacies: some methodological issues. Drug Saf. 2001;24:929-938.
5. Burnett I, Clarke J. Methodological bias in over the counter analgesic tolerability study. Poster presented at EULAR 2002.
6. M-Tag. Pty Ltd, Determining screening failure rate for an OTC analgesic study using a general practice research network. Available from GlaxoSmithKline Consumer Healthcare Australia. December 2001.
7. Moore N, Charlesworth A, van Ganse E, et al. Risk factors for adverse events in analgesic drug users: results from the PAIN study. Pharmacoepidemiol Drug Saf. 2003;12:601-610.
8. Moore N, Le Pare JM, van Ganse E, et al. Tolerability of ibuprofen, aspirin and paracetamol for the treatment of cold and flu symptoms and sore throat pain. Int J Clin Pract. 2002;56:732-734.
9. Moore N, van Ganse E, Le Parc JM, et al. The PAIN study: Paracetamol, aspirin and ibuprofen new tolerability study. A large-scale, randomised clinical trial comparing the tolerability of aspirin, ibuprofen and paracetamol for short-term analgesia. Clin Drug Invest. 1999;18:89-98.
10. Boureau F, Schneid H, Zeghari N, et al. The IPSO study: ibuprofen, paracetamol study in osteoarthritis. A randomised comparative clinical study comparing the efficacy and safety of ibuprofen and paracetamol analgesic treatment of osteoarthritis of the knee or hip. Ann Rheum Dis. 2004;63:1028-1034.
11. Dieppe P, Bartlett C, Davey P, et al. Balancing benefits and harms: the example of non-steroidal anti-inflammatory drugs. BMJ. 2004;329:31-34.